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Abstract
The emergence and spread of Plasmodium falciparum resistance to first-line antimalarials creates
an imperative to identify and develop potent preclinical candidates with distinct modes of action.
Here, we report the identification of MMV688533, an acylguanidine that was developed following
a whole-cell screen with compounds known to hit high-value targets in human cells. MMV688533
displays fast parasite clearance in vitro and is not cross-resistant with known antimalarials. In a
P. falciparum NSG mouse model, MMV688533 displays a long-lasting pharmacokinetic profile
and excellent safety. Selection studies reveal a low propensity for resistance, with modest loss
of potency mediated by point mutations in PfACG1 and PfEHD. These proteins are implicated
in intracellular trafficking, lipid utilization, and endocytosis, suggesting interference with these
pathways as a potential mode of action. This preclinical candidate may offer the potential for a
single low-dose cure for malaria.
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INTRODUCTION
Worldwide, malaria mortality and incidence were estimated to decrease by 60 and
37%, respectively, from 2000 to 2015. This positive trend came to an end in 2016,
with cases and deaths plateauing, and 229 million cases and 409,000 deaths estimated
in 2019 (1). Plasmodium falciparum parasite resistance to first-line artemisinin-based
combination therapies continues to rise in Southeast Asia and now threatens Africa (2-4).
Despite extensive global initiatives, malaria drug discovery and development efforts have
encountered major obstacles to identifying chemical compounds with alternate modes of
antiplasmodial action that do not readily succumb to parasite resistance (5).

Author Manuscript

To address these barriers, we applied an atypical drug discovery approach leveraging
research and development programs on human diseases at Sanofi. Classical approaches rely
on the identification of compounds that are both potent and specific against Plasmodium
parasites, but our strategy first identified Plasmodium-active compounds from a library
of chemical matter with known activity against human targets selected from discovery
programs through to phase 3 clinical trials. Compounds active against P. falciparum asexual
blood-stage parasites were then chemically optimized to increase antiplasmodial specificity
and reduce host toxicity risks. Our approach led to the identification of several highly potent
chemical series, including the acylguanidines that are exemplified by MMV688533. This
molecule is shown herein to act via a previously undescribed mode of action that only
allowed P. falciparum parasites to acquire low-grade resistance under drug pressure.

RESULTS
Author Manuscript

Acylguanidines are potent antiplasmodial compounds with promising physicochemical
properties

Author Manuscript

A bioinformatics-mediated analysis of Sanofi drug discovery programs led to the selection
of 450 compounds active against one of 33 human targets for which putative orthologs
were found in P. falciparum, Trypanosoma brucei, Trypanosoma cruzi, and/or Leishmania
donovani. We also included 350 compounds active against any one of 28 Sanofi high
priority human targets. The screening of these 800 compounds against cultured P. falciparum
asexual blood-stage parasites resulted in the identification of 120 compounds whose half
maximal growth inhibition concentration (IC50) was ≤1 μM, corresponding to a 15% hit
rate. As a comparison, classical random screening approaches have previously yielded 0.35
to 0.68% hit rates (6-8), highlighting a benefit of our drug discovery strategy. We then
applied hit selection criteria including suitable physicochemical properties (www.mmv.org/
research-development/information-scientists) and IC50 values <1 μM against a panel of
drug-sensitive or -resistant P. falciparum strains and also screened an additional set of 800
analogs of preferred hits to expand the structure-activity relationships (SARs) (9). This work
yielded six chemical scaffolds for medicinal chemistry optimization. Here, we describe the
acylguanidine series, which includes the initial hit MMV668603 that was potent against P.
falciparum NF54 asexual blood stages and had an IC50 of 1.7 nM. This hit originated from
the dimerization of a compound chemically related to cariporide, an inhibitor of human
Na+/H+ exchanger isoform 1 that has anticancer and cardioprotective properties (10, 11). A
hit to lead optimization program, including SAR studies, led to the intermediate compound
Sci Transl Med. Author manuscript; available in PMC 2022 July 21.
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MMV669851 and the eventual preclinical candidate MMV688533 (Fig. 1A). Compared
with MMV668603, the candidate MMV688533 did not contain a diazo moiety, showed
improved solubility (from <10 to >1000 μg/ml at pH 1) and intestinal permeability, and
retained potent antiplasmodial activity (Fig. 1A and table S1, A and B).
MMV688533 displayed a fast asexual blood-stage parasite killing rate and high potency
against P. falciparum and P. vivax strains in vitro and ex vivo

Author Manuscript

MMV688533 was highly potent against multiple P. falciparum strains, with IC50 values in
the low nanomolar range and no evidence of reduced potency against parasite lines resistant
to antimalarials currently in the clinic or in development (table S1C). These data suggest
that MMV688533 might have a distinct mode of antiplasmodial action. MMV688533
also showed excellent ex vivo activity against asexual blood-stage parasites from fresh P.
falciparum isolates from Ugandan patients (median IC50 = 1.3 nM, range = 0.02 to 6.3
nM, N = 143). In Papua Indonesia, where both P. falciparum and P. vivax are endemic,
MMV688533 remained potent in ex vivo assays, with similar IC50 values against both
parasite species (medians of 18.9 and 12.0 nM respectively; Table 1). MMV688533 was as
potent as, if not more so than, either chloroquine or piperaquine against P. falciparum and P.
vivax clinical field isolates (Table 1). This compound did not show potent activity against P.
falciparum liver stages or male and female gametes (table S1D).
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MMV688533 displayed a fast-killing profile in the parasite reduction ratio (PRR) assay (12),
as demonstrated by a log10 PRR of nearly 5, corresponding to a decrease of parasitemia
by nearly five orders of magnitude during a single 48-hour intraerythrocytic developmental
cycle (Fig. 1B). Over 24 hours this profile is similar to dihydroartemisinin, the active
metabolite of artemisinins that constitute the fastest-acting class of antimalarials available to
date (13). This compound displayed very rapid parasite killing when tested over the range of
1× to 30× IC50 (Fig. 1C), as well as very low cytotoxicity (table S1E).
MMV688533 displayed fast and potent in vivo efficacy and favorable in vitro absorption,
distribution, metabolism, and excretion and in vivo pharmacokinetic properties
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MMV688533 was highly efficacious in the nonobese diabetic–severe combined
immunodeficient NOD-scid interleukin-2Rγnull (NSG) mouse model of P. falciparum
asexual blood-stage infection (14), with a single oral dose of 5 mg/kg resulting in a rapid
reduction in parasitemia to below the limit of detection within 48 hours, followed by
recrudescence to 1% by day 18. By comparison, vehicle-treated mice attained a parasitemia
of 8 to 10% by day 5 (Fig. 1D). These data predicted a 90% effective dose (ED90) of 2
mg/kg, corresponding to the single dose required to reduce parasitemia by >90% by day
7 compared to vehicle-treated mice (Fig. 1, D and E, and table S1F). Four consecutive
daily doses of 0.9 mg/kg produced >90% reduction in parasitemia by day 7. One dose
of MMV688533 (at least 5 mg/kg) cleared parasites as rapidly as dihydroartemisinin (50
mg/kg; Fig. 1D). Pharmacokinetic-pharmacodynamic (PK/PD) modeling predicted an in
vivo minimal parasiticidal concentration of 20.3 ng/ml (table S1G).
PK studies indicated a low plasma clearance (CL) in mice, rats, and dogs (table S1H). When
tested on purified cytochrome P450 enzymes, MMV688533 did not show high inhibitory

Sci Transl Med. Author manuscript; available in PMC 2022 July 21.
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potency (table S1I). MMV688533 also displayed a moderate to high volume of distribution
(Vss: 1.4 liters/kg in mice and 4.7 liters/kg in Beagle dogs) and a moderate to long half-life
in all species (3.2 hours in mice and 50.7 hours in dogs) (table S1, J and N). The oral
bioavailability of MMV688533 was >70% in rodent species (table S1J). Human CL and Vss
parameters calculated from rat and dog allometry were predicted to be inferior to 5% of
the hepatic blood flow using two methods (see Materials and Methods) and 540 liters for a
70-kg patient, respectively. The predicted half-life of MMV688533 in humans was greater
than 100 hours (table S1P).

Author Manuscript

We then predicted an efficacious single dose in humans based on the following: (i) the
minimal parasiticidal concentration derived from PK/PD modeling of the Pf NSG data (table
S1, F and G); (ii) the Kkill derived from in vitro PRR studies (Fig. 1B); (iii) the PK in mouse,
rat, and dog used in allometric scaling (table S1, J to P); and (iv) a biopharmaceutical model
(GastroPlus). This latter model predicted that at least 50% of a 500-mg dose was absorbed
when administered in fed conditions. A 100-mg dose was absorbed up to 70% in fasted
conditions, while at this dose, the food effect was less than 30%. Using these parameters,
a single oral administration of 30 mg of MMV688533 in humans would be predicted to
maintain its concentration above the minimal parasiticidal concentration over a period of
96 hours, which covers two P. falciparum erythrocytic replication cycles, and to reduce
parasitemia by at least 6 logs when a conservative in vitro log PRR value was capped at
3. Similarly, a dose of 24 mg is predicted to reduce parasitemia when the in vitro log PRR
value of 5 was used. A single-dose treatment with 66 mg of MMV688533 is predicted to
reduce parasitemia by 12 logs, suggesting very favorable characteristics for future clinical
studies.

Author Manuscript

MMV688533 revealed a favorable tolerability profile
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In silico toxicity predictions did not raise any safety alerts other than a moderate phototoxic
risk (table S1Q), which proved minimal when tested in MMV688533-treated BALB/c 3T3
mouse fibroblasts exposed to ultraviolet light. Genotoxicity testing with MMV688533,
including preliminary Ames and micronucleus assay, was negative. Profiled on a receptor/
enzyme panel, MMV688533 displayed micromolar affinity for calcium and chloride
channels as well as for benzodiazepine and dopamine receptors (table S1R). Considering its
similarity with cariporide, cardiovascular parameters were assessed in detail. MMV688533
had a modest effect on the human Ether-ágo-go-Related Gene (hERG) channel with an
IC50 of 30 and 4.6 μM when measured by automatic and manual patch clamp (table S1S),
respectively. Inhibition studies with Nav1.5 and Cav1.1 ion channels yielded IC50 values
of 14 and 2.1 μM, respectively (table S1S). When tested in the Purkinje fiber assay,
MMV688533 induced mild effects that were not suggestive of a torsadogenic profile.
However, because of the limited solubility of the compound in the conditions of this
study, a full cardiosafety in vitro evaluation at higher concentrations was not possible.
Therefore, in vivo studies were conducted to better assess potential cardiovascular safety
risks. Continuous intravenous administration of MMV688533 (at 10, 20, and 30 mg/kg) to
anesthetized guinea pigs did not affect blood pressure, heart rate, the electrocardiogram RR
or QT intervals, or the QRS complex. In summary, in silico, in vitro, and in vivo safety
studies with MMV688533 did not raise any measurable cardiotoxicity alerts.

Sci Transl Med. Author manuscript; available in PMC 2022 July 21.

Murithi et al.

Page 5

Author Manuscript

Preliminary safety was assessed in rats and dogs via oral treatment and drug exposure
measurements (toxicokinetics: table S1, T and U). In a non-Good Laboratory Practice (GLP)
2-week toxicity study in Sprague-Dawley rats, no clinically apparent changes were observed
at 12.5, 25, and 50 mg/kg dose levels. In this study, 12.5 mg/kg per day exposure was
considered the no-observed effect level (NOEL) due to an increase of liver biomarkers and
microscopic changes (foamy macrophages and microscopic changes) at the two highest
doses. In a non-GLP 2-week toxicity study in beagle dogs (0.5 and 1 mg/kg per day once
daily and 2 mg/kg per day every other day), only minimal transient changes of no safety
concern were detected. In conclusion, the noobserved-adverse-effect level (NOAEL) was
declared at 1 mg/kg and the corresponding cumulated exposure over 14 days was 14-fold
higher than that predicted for a 30-mg single dose in humans (table S1V). Such a predicted
safety margin was judged promising enough to progress MMV688533 to more detailed
regulatory preclinical studies before first-in-human clinical trials.

Author Manuscript

MMV688533 is maximally potent against P. falciparum rings and early trophozoite stages
To assess the timing of MMV688533 action, we used an in vitro asexual blood-stage
susceptibility assay that measures compound activity against early and late rings, early
and late trophozoites, and schizonts (15). The assay was validated by the stage-specific
susceptibility profiles of dihydroartemisinin, chloroquine, and the PI4K inhibitor KAI407
(16), which showed the expected peak activities on early rings, rings and trophozoites, and
schizonts, respectively (15). MMV688533 and dihydroartemisinin shared a similar activity
profile, with early rings to early trophozoites being the most susceptible, whereas schizonts
were the least affected (Fig. 2A).

Author Manuscript

Ramping selections with P. falciparum asexual blood-stage parasites yield low-grade
resistance to MMV688533

Author Manuscript

To identify possible resistance mechanisms to the acylguanidine MMV688533, we
performed single-step in vitro resistance selections by exposing triplicate flasks of
2 × 109 wild-type Dd2-B2 parasites to 3× IC50 of MMV688533. These single-step
selections did not yield resistant parasites after 60 days, suggesting a low propensity
for resistance development for this compound. This was further confirmed in ramping
selections, which entailed gradually increasing the drug pressure from 1 to 11× IC50
on triplicate flasks of 2 × 108 3D7-A10 parasites each over a 6-month period. This
selection yielded only very low-grade resistance, with a two- to fivefold IC50 increase
in each of the three drug-pressured lines (Fig. 2B and Table 2). Whole-genome
sequencing (WGS) of four resistant clones obtained from across the three pressured
lines identified single-nucleotide polymorphisms (SNPs) in five genes: a conserved
Plasmodium protein of unknown function (PF3D7_0910300), an Eps15 homology domain
(EHD)–containing protein (PF3D7_0304200), a conserved Plasmodium protein of unknown
function (PF3D7_0510100), a putative RNA pseudouridylate synthase (PF3D7_0511500),
and the putative adenosine 5′-triphosphate synthase (C/AC39) subunit (PF3D7_1464700)
(Table 2 and table S2).
Of note, all four clones (sel. 533-CL1 to 533-CL4, named after the last three digits of
the selecting compound MMV688533 followed by the clone name) carried G98V (clones

Sci Transl Med. Author manuscript; available in PMC 2022 July 21.
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sel. 533-CL1 and sel. 533-CL4), W286R (clone sel. 533-CL2), or T92* stop codon
(clone sel. 533-CL3) mutations in PF3D7_0910300. These mutations were identified from
three separately drug-pressured lines, suggesting a key role for this protein in conferring
resistance to MMV688533. PF3D7_0910300, which we herein name P. falciparum
acylguanidine 1 (PfACG1) in reference to the acylguanidine series, is a conserved
Plasmodium protein of unknown function. Clone sel. 533-CL4, which also has a D218Y
mutation in gene PF3D7_0304200 (PfEHD), displayed the highest level of resistance to
MMV688533 (4.6-fold IC50 shift) (Fig. 2B and Table 2). This suggested an additional
role for PfEHD in enhancing parasite resistance to the compound. On the basis of these
observations, namely, the presence of PfACG1 mutations in all the selected clones and the
apparent boost in resistance associated with an additional PfEHD D218Y mutation in sel.
533-CL4, we hypothesized that these two proteins, out of the five proteins identified using
WGS, play a crucial role in mediating resistance to MMV688533. We chose to not assess
the other three genes listed above as each harbored a mutation observed from only a single
line, and unlike PF3D7_0304200, none of these three were associated with an increased
degree of resistance (Table 2).
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To test this hypothesis, we introduced the G98V and W286R mutations in PfACG1 and the
D218Y mutation in PfEHD individually into wild-type 3D7-A10 parasites using a CRISPR
Cas9 gene-editing strategy. This yielded the edited lines ed. 3D7 ACG1G98V, ed. 3D7
ACG1W286R, and ed. 3D7 EHDD218Y. The G98V mutation in the ed. 3D7 ACG1G98V line
conferred comparable levels of resistance to the corresponding selected clone sel. 533-CL1,
whereas the W286R mutation in the ed. 3D7 ACG1W286R line only contributed around half
of the resistance observed in sel. 533-CL2 (Fig. 2B and Table 2). The D218Y mutation
in PfEHD alone was insufficient to confer resistance. To test whether SNPs in PfACG1
are needed to obtain higher-grade resistance to MMV688533, we introduced the D218Y
mutation into the background of the clone sel. 533-CL1, using a CRISPR-Cas9 strategy.
This clone harbors the G98V mutation in PfACG1. The resulting sel. ed. 533-CL1EHD-D218Y
line showed a 6.2-fold shift in IC50 compared to wild-type parasites, comparable to the
4.6-fold shift in clone sel. 533-CL4. These results provide evidence that the D218Y mutation
in PfEHD enhances resistance to MMV688533 when the G98V mutation is already present
in PfACG1.
Conditional knockdown of the resistance determinants PfACG1 and PfEHD does not affect
in vitro parasite growth

Author Manuscript

To further explore the role of PfACG1 and PfEHD, we engineered conditional knockdown
(cKD) parasite lines in which we could regulate protein expression levels via the
Tetracycline resistance Repressor - RNA helicase DOZI (development of zygote inhibited)
(TetR-DOZI) System (17). Normal protein levels were maintained by culturing parasites
in the presence of anhydrotetracycline (aTc) (fig. S1A). Western blot analysis of these
lines, which harbored a C-terminal 2× hemagglutinin (HA) epitope tag fused to each gene
product, confirmed the expression of PfACG1 and PfEHD in the presence of aTc (Fig.
2C and fig. S1B). aTc withdrawal resulted in the loss of protein expression, confirming
efficient knockdown of the proteins. Despite the substantial knockdown observed from the
Western blots, assessment of growth over two replicative cycles revealed that PfACG1 and

Sci Transl Med. Author manuscript; available in PMC 2022 July 21.
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PfEHD cKD parasites, maintained in the absence of aTc, were able to progress through
the intraerythrocytic stage life cycle similar to controls. These results suggest that loss
of function of either protein does not affect viability under normal culture conditions
(Fig. 2C). To test for ex vivo compound-target interactions, we determined the IC50 of
MMV688533 against wild-type versus knockdown conditions of PfACG1 and PfEHD.
Knockdown of PfACG1 and PfEHD protein levels did not result in differential susceptibility
to MMV688533 (Fig. 2D), providing evidence that these proteins are not directly targeted by
MMV688533.
MMV688533-resistant parasites do not show cross-resistance to current antimalarials
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To test whether resistance to MMV688533 might affect the efficacy of clinical antimalarials,
we tested the 3D7 ACG1G98V and 3D7 ACG1W286R edited lines as well as the resistant
clone sel. ed. 533-CL1EHD-D218Y for cross-resistance against a diverse panel of 11 known
antimalarials. This study used 72-hour asexual blood-stage parasite susceptibility assays
across a range of drug concentrations (Fig. 2E and table S3). Neither the individual G98V
and W286R mutations in PfACG1 nor the multiple SNPs in sel. ed. 533-CL1EHD-D218Y
conferred cross-resistance to these drugs, implying that MMV688533 has a different mode
of action against P. falciparum.
PfACG1 and PfEHD localize primarily to distinct intracellular parasite vesicles
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To interrogate the subcellular localization of PfACG1 and PfEHD, we performed
immunofluorescence studies with a variety of cellular comarkers. We generated a doubly
tagged recombinant NF54attB parasite line expressing a 3×HA tag at the C terminus of the
PfEHD endogenous locus as well as a stably integrated transgenic copy of PfACG1 that was
C-terminally tagged with enhanced green fluorescent protein (eGFP; NF543×HA-EHDattB
ACG1-eGFP).
PfACG1-eGFP mainly localized to foci around the digestive vacuole (DV) of the parasite
with residual labeling observed around the parasite nucleus (Fig. 2F and figs. S4 and S6).
PfEHD likewise appeared in foci that localized mostly to the parasite periphery as well as
close to the DV. Other foci were also other observed, although to a lesser extent, throughout
the parasite cytoplasm (Fig. 2F and figs. S5 and S7). Colabeling using anti-HA and anti-GFP
antibodies to assess colocalization of PfACG1 with PfEHD showed no overlap between the
two fluorophores (Fig. 2G).
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Most of the eGFP signal for the PfACG1-fusion protein was observed adjacent to the DV, so
we performed costains using antibodies directed to Plasmodium falciparum chloroquine
resistance transporter (PfCRT), Plasmodium falciparum multidrug resistance protein 1
(PfMDR1), or plasmepsin II, which are known to localize to this lysosome-like Plasmodium
organelle (Fig. 2H and figs. S4, A and B, and S6, B and C). This confirmed some proximity
to the DV, but imaging showed only infrequent and seemingly random overlap between
PfACG1 and either of the DV transmembrane proteins PfCRT and PfMDR1. To investigate
whether PfACG1 could overlap with neutral lipid bodies, which are often localized adjacent
to the parasite DV (18), we carried out costains using LipidTOX and Nile Red (Fig. 2I and
fig. S4, C to F, and S6, D to G). Not all eGFP-positive foci exclusively overlapped with these
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lipid bodies, although we did observe frequent juxtaposition. These observations point to the
possibility that PfACG1 partially associates with lipid storage bodies localized close to the
DV.
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Despite our detection of an eGFP signal close to the nucleus, no overlap was detected
upon costaining for the parasite endoplasmic reticulum (ER) using antibodies specific
for PDI (protein disulfide isomerase; Fig. 2J and fig. S6, H and I). Instead, the eGFP
signal showed some overlap with antibodies to ERD2 and PMT (phosphoethanolamine
N-methyltransferase), which represent markers for the cis- and trans-Golgi (19, 20),
respectively (Fig. 2K and figs. S4, G to J, and S6, J and K). To test whether PfACG1
localized to Rab-positive vesicles that are known mediators of vesicular traffic, we costained
with Rab5A, Rab5B, and Rab7 antibodies. We observed infrequent overlap, similarly to
costains performed with antibodies against K13, a marker for hemoglobin endocytosis (21,
22) (Fig. 2L and figs. S4, K to N, and S6, L and O). Along these lines, no colocalization
was observed for PfACG1 and coronin, a protein involved in F-actin organization that has
recently been associated with in vitro resistance of early ring stages to artemisinins (23)
(fig. S4O). Last, we assessed colocalization to the parasite mitochondrion using MitoTracker
Deep Red, as well as to the apicoplast as visualized with anti–acyl carrier protein (ACP)
antibodies. No overlap was observed between PfACG1-eGFP and those organelles (fig. S4,
P and Q).
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We detected PfEHD-positive foci that were close to the DV but did not colocalize with
PfCRT, similar to our observations with PfACG1 (Fig. 2M and fig. S7, B and C). Costains
using LipidTOX occasionally colocalized some of the HA-labeled PfEHD vesicles with
neutral lipid bodies (Fig. 2N and figs. S5, A and B, and S7D). To test for possible PfEHD
association with the parasite ER or the Golgi apparatus, we used antibodies directed to PDI,
ERD2, or PMT. Frequent proximity and partial overlap were observed between PfEHD
positive foci and the ER-resident markers PDI and BIP, whereas the Golgi labeling (with
ERD2 and PMT) revealed no obvious association between PfEHD and this organelle (Fig.
2, O and P, and figs. S5, C to F, and S7, E to H). In mammalian cells, EHD-containing
proteins, serving as protein interaction platforms, are known to primarily function as key
regulators in endocytosis (24). To explore whether PfEHD could play a similar role in
protein and lipid trafficking processes in parasites, we performed immunofluorescence
studies using antibodies to coronin and Rab proteins. We found that PfEHD vesicles that
localized close to the parasite membrane frequently overlapped with coronin, hinting at
a possible interaction between the two proteins (Fig. 2Q and figs. S5, G to J, and S7,
I and J). Immunofluorescence assays carried out with the panel of Rab antibodies (anti
Rab5A, -Rab5B, -Rab5C, -Rab7, and -Rab11A) as well as antibodies to K13 revealed some
juxtaposition of Rab-positive vesicles and K13-positive foci with PfEHD (figs. S5, L to P,
and S7K). In contrast, when assessing potential PfEHD association with the apicoplast using
anti-ACP antibodies, we did not observe overlap between the fluorophores (fig. S5Q).

DISCUSSION
Here, we report a potent antimalarial, MMV688533, developed after a whole-cell screen
of Sanofi compounds active on defined human targets that were assayed for potency

Sci Transl Med. Author manuscript; available in PMC 2022 July 21.

Murithi et al.

Page 9

Author Manuscript

against P. falciparum asexual blood-stage parasites. Our screen of 800 compounds yielded
a high hit rate, with 120 showing submicromolar antiplasmodial activity. Physicochemical
analysis identified acylguanidines as the most promising series, with subsequent SAR-based
lead optimization yielding MMV688533. PRR assays revealed rapid killing in vitro, with
MMV688533 reducing the parasite load by >3 log within 24 hours after drug addition,
similar to dihydroartemisinin and considerably faster than the comparator first-line drugs
chloroquine and pyrimethamine. MMV688533 also displayed minimal toxicity against
mammalian cells, slow clearance, and a long half-life, predicted at 100 hours in humans.
Single-dose efficacy in the P. falciparum–infected NSG mouse model was excellent, with
parasite clearance and delayed recrudescence observed at doses as low as 5 mg/kg. These
data highlight the therapeutic potential of this class of antimalarials.
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Whole-cell screens for antimalarials have yielded multiple potent antimalarials, which have
encountered parasite resistance at frequencies and levels that pose a concern for their further
development as curative drugs (25). For example, inhibitors of the drug targets PfATP4 or
PfeEF2 can select for resistance from upwards of 107 parasites, with SNPs that can cause
IC50 increases of a few up to several ten- or hundred–fold (26-28). In contrast, using these
same selection procedures (29), MMV688533 yielded no resistance when used to pressure
even large parasite inocula (6 × 109). Low-grade resistance could only be achieved by
using a ramping method of gradually increasing drug concentrations over a 6-month period.
Parasite clones from these selections showed two- to fivefold higher IC50 values against
MMV688533. WGS identified two distinct point mutations or a stop codon in the PfACG1
gene in all clones assayed from three independent selections. Upon gene editing, both point
mutations afforded only a twofold IC50 increase. One clone also harbored a point mutation
in PfEHD, which, upon editing into a PfACG1 mutant line, resulted in a sixfold higher
IC50 relative to the drug-sensitive 3D7 line. Other editing results showed that this PfEHD
mutation on its own was insufficient to mediate parasite resistance. We note that three other
genes were observed to each harbor a single nonsynonymous mutation. These mutations
occurred separately in only one of the three flasks and may be attributable to stochastic
events that arise naturally at low frequency during extended in vitro culture (30, 31).
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PfACG1 and PfEHD are both considered to be dispensable for P. falciparum asexual blood
stage growth in vitro (32), consistent with our cKD data in which no evident growth
inhibition occurred despite virtually complete protein knockdown (Fig. 2C). PfACG1,
previously annotated as a conserved protein of unknown function, is only conserved among
Apicomplexan parasites of the genus Plasmodium, with minimal (~20%) amino acid identity
to Cryptosporidium andersoni and Cryptosporidium muris. Protein sequence analysis shows
a signal peptide at the N terminus and a single transmembrane domain at the C-terminal end.
Little else is known about this protein. PfEHD contains a highly conserved EHD involved
in protein-protein interactions and found in proteins that play a role in endocytosis (24).
PfEHD has previously been linked to vesicular trafficking in P. falciparum parasites (33).
PfACG1 and PfEHD did not colocalize in our immunofluorescence assays. Nonetheless,
PfACG1 colocalized with the neutral lipid markers LipidTOX and Nile Red, as well as
the Golgi marker ERD2 that mediates protein retention in the ER and PMT that plays
a critical role in phosphatidylcholine synthesis. These observations suggest that PfACG1
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might play a role in vesicular trafficking or storage of lipids. In contrast, PfEHD showed
some colocalization with the ER markers ERD2 and PDI as well as the actin-binding protein
coronin. PfEHD has previously been shown to be an interacting partner of AP-2μ, an adaptor
protein that is essential for endocytosis and intracellular trafficking (34). Together, these
data suggest that PfACG1 and PfEHD might be involved in related intracellular trafficking
pathway(s) acted upon by MMV688533, which would be consistent with our observation
that mutations in both proteins contributed to resistance to this compound. These results,
along with lack of chemical-genetic interaction observed using the cKD lines (Fig. 2C),
suggest that neither of these two proteins is the actual target and that they function instead
as resistance mediators. These data suggest that MMV688533’s mode of action involves
inhibition of vesicular trafficking and/or lipid storage pathways. At present, this compound
can be considered “targetless,” a feature shared by multiple antimalarials in clinical use or
advanced stages of development, including lumefantrine, quinine, artemisinin derivatives,
OZ439, and KAF156 (25, 35).
Further research is clearly required to define the mode of action of MMV688533. One
limitation of our current study is that we did not define how PfACG1 and PfEHD mediate
low-level resistance, nor did we establish the biological roles of these proteins during
parasite intraerythrocytic development. Additional studies are also required to identify the
cellular targets of MMV688533. Last, our dosing predictions for first-in-human study are
based, in part, on allometric scaling of PK data from animal models and will benefit from
further refinement after completion of phase 1 clinical trials.
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In conclusion, we report that the acylguanidine MMV688533 has favorable fast-acting and
long-lasting PK/PD properties. Drug selection studies showed that parasites could only
acquire low-grade resistance with large inocula, and no cross-resistance was observed with
established antimalarials or advanced preclinical candidates. These data suggest an alternate
mode of action for MMV688533, which appears to involve lipid-associated intracellular
trafficking of essential components. The promising preclinical therapeutic margin and low
single doses predicted to be efficacious in humans should improve compliance and enable a
low cost of goods.

MATERIALS AND METHODS
Study design
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This study’s objective was to harness the potential of compounds with known drug-like
properties, which had earlier fueled discovery and development pipelines in several
therapeutic areas, as a source of potential antimalarial candidates with previously
undiscovered modes of actions. Screening against P. falciparum asexual blood-stage
parasites led us to identify an acylguanidine chemical series with promising potency and
physicochemical properties. Medicinal chemistry yielded analogs with improved parasite
selectivity and PK properties. Prioritized compounds were assayed for in vivo efficacy in
a humanized mouse model of P. falciparum infection. Preclinical toxicity studies with 4or 14-day exposures were then performed in rats and dogs to predict a safety margin for
clinical use. Cross-resistance and drug selection studies were used to test for resistance
liabilities. cKD and gene-editing experiments, along with immunofluorescence imaging,
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were leveraged to conduct exploratory studies into compound mode of action. All assays
were performed with multiple repeats with technical duplicates or triplicates, with positive
and negative controls, as indicated in Materials and Methods and in figure legends.
MMV688533 synthesis
MMV688533 was synthesized as described in Supplementary Materials and Methods and
illustrated in fig. S8.
Compound potency against P. falciparum and P. vivax parasites
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Antimalarial activity against resistant culture-adapted strains of P. falciparum was measured
with the modified [3H]-hypoxanthine incorporation assay, as previously reported (36).
Compounds, field locations, and sample collections are described in Supplementary
Materials and Methods. Ex vivo potency assays against P. falciparum and P. vivax clinical
isolates are described below.
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In Papua Indonesia, drug susceptibility was measured in P. vivax and P. falciparum isolates
using a protocol modified from the World Health Organization microtest (37-39). Briefly,
200 μl of a 2% hematocrit of blood media mixture, consisting of RPMI 1640 medium
plus 10% AB+ human serum for P. falciparum or McCoy’s 5A medium plus 20% AB+
human serum for P. vivax, was added to each well of predosed drug plates containing 11
serial concentrations (twofold dilutions) of the test antimalarials (maximum concentration
shown in parentheses) chloroquine (2993 nM), piperaquine (1029 nM), mefloquine (338
nM), artesunate (49 nM), and MMV688533 (237 nM). A candle jar was used to mature
the parasites at 37°C for 35 to 56 hours. Incubations were stopped when >40% of the
ring-stage parasites had reached the mature schizont stage in the drug-free control wells,
as determined by light microscopy. Parasite growth was quantified by nucleic acid staining,
and parasitemias were measured using flow cytometry. Parasite growth was quantified
for each drug concentration and normalized to the control well. The dose-response data
were analyzed using nonlinear regression analysis, and the IC50 values were derived
using an inhibitory sigmoid Emax model (In vitro Analysis and Reporting Tool; IVART7).
Ex vivo IC50 data were only used from predicted curves where the Emax and E0 were
within 15% of 100 and 1, respectively. The drug plate quality was assured by running
schizont maturation assays with the P. falciparum chloroquine-resistant strain K1 and the
chloroquine-sensitive strain FC27. For data quality control, raw flow cytometry values
were analyzed by two independent operators and compared. If the raw dose-response data
derived by the two operators led to a marked shift in IC50 estimates for any of the drugs,
they were reviewed and adjusted by a third operator. Ethical approval for this study was
obtained from the Eijkman Institute Research Ethics Commission of the Eijkman Institute
for Molecular Biology, Jakarta, Indonesia; the Human Research Ethics Committee of the
Northern Territory Department of Health and Families; and the Menzies School of Health
Research, Darwin, Australia.
In Africa, drug susceptibility was measured in P. falciparum isolates using a protocol
summarized as follows: All MMV compounds were dissolved in dimethyl sulfoxide
(DMSO) to a final concentration of 0.5 to 10 mM and stored at −20°C. On the day of
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assay, 2 μl of DMSO stock drug was diluted in 498 μl of complete RPMI media [RPMI
1640 medium supplemented with 25 mM Hepes, 0.2% NaHCO3, 0.1 mM hypoxanthine,
gentamicin (100 μg/ml), and 0.5% Albumax I (Invitrogen)]. Diluted drugs were not stored
for longer than 24 hours. Drugs were serially diluted threefold in 96-well assay plates in
complete media containing 0.4% DMSO, to a final volume of 50 μl, in columns 1 to 10.
Column 11 contained drug-free controls, while column 12 contained uninfected red blood
cell (RBC) controls. Parasitized whole-blood samples were washed three times with RPMI
(without AlbuMAX) media at 37°C and then resuspended in fresh RPMI media to a final
hematocrit of 2%. One hundred fifty microliters of the parasite culture was added to each
well into the assay plate for final parameters of 0.2% parasitemia and 2% hematocrit. Plates
were incubated for 72 hours in a humidified modular incubator under a tri-gas mixture (5%
O2, 5% CO2, and 90% N2) at 37°C. Plates were then stained with SYBR Green I, and
fluorescence was determined using a BMG Fluostar Optima plate reader at an excitation of
485 nm and an emission of 530 nm (40). Fluorescence data were curve-fitted to estimate
IC50 values (GraphPad Prism 7). For each isolate, a Z′ factor was calculated from drug-free
positive and negative controls (eight parasitized RBC wells and eight uninfected RBC wells,
respectively).
P. falciparum culture-adapted lines
Asexual blood-stage parasites were cultured at 3% hematocrit in O+ human erythrocytes
in RPMI 1640 medium supplemented with 50 μM hypoxanthine, NaHCO3 (2.25 g/liter), 2
mM L-glutamine, 25 mM Hepes, 0.5% (w/v) AlbuMAXII (Invitrogen), and gentamycin (10
μg/ml) at 37°C in flasks gassed with 5% O2/5% CO2/90% N2. The P. falciparum 3D7-A10
and Dd2-B2 clones used for the selections and drug assays, as well as the NF54attB line
used to express pfACG1-eGFP and pfehd-3×HA, have been previously reported (15, 41, 42).
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Determination of the in vitro rate of killing (PRR)
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As described in (12), the compound IC50 was determined via [3H]-hypoxanthine
incorporation. For PRR assays, 105 3D7A parasite cultures were exposed to MMV688533 at
10× IC50 for 120 hours. Drug treatment was renewed every 24 hours over the entire period.
Parasite aliquots were taken from the treated cultures every 24 hours, with drug washout,
throughout the 5-day treatment period. Freshly obtained human RBCs and new media
were then added to the drug-free parasites, which were serially diluted in quadruplicate
into 96-well plates. Growth in individual wells was detected after 3 and 4 weeks using
[3H]-hypoxanthine incorporation. The number of viable parasites was determined by the
dilution down to which growth was observed. The rate of killing was represented by the log
of viable parasites as a function of treatment duration. PRR was defined as the log-linear
reduction of viable parasites over 48 hours.
Determination of efficacy and PK profiles in the Pf NSG mouse model
Assays used the P. falciparum Pf3D70087/N9 parasite line (14), which was propagated in
23- to 28-g female NOD-scid interleukin-2Rγnull (NSG; Charles River, France) mice at The
Art of Discovery (TAD).
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For in vivo efficacy trials, immunodeficient female NSG mice were engrafted with a
minimum of 40% human erythrocytes circulating in peripheral blood during the entire
experiment. Each mouse was inoculated with a 50 to 75% hematocrit erythrocyte suspension
(Basque Center of Transfusion and Human Tissues, Galdakao, Spain and Bank of Blood
and Tissues, Barcelona, Spain) in RPMI1640 medium, 25% (v/v) decomplemented human
serum, and 3.1 mM hypoxanthine. Intraperitoneal and/or intravenous (via tail lateral
vein) injections were done once daily until the end of the drug administration period.
Humanized NSG mice were infected with peripheral blood from CO2-euthanized donor
mice harboring 5 to 10% parasitemia. The humanized mice of the efficacy study were
infected by inoculation of 0.3 ml of the infected-erythrocyte suspension by the lateral vein
of the tail. For treatment, drug was administered at day 1 (~1% patent parasitemia) (P0)
by oral gavage (volume 10 ml/kg of body weight). To measure the therapeutic response, 2
μl of peripheral tail blood from P. falciparum–infected mice was stained with antibodies to
TER-119–phycoerythrin (a marker of murine erythrocytes; Miltenyi Biotec) and SYTO-16
(nucleic acid dye) and analyzed by flow cytometry (Attune NxT Acoustic Focusing Flow
Cytometer, Invitrogen). Drug effect on circulating P. falciparum Pf3D70087/N9 parasites
was assessed by microscopy (Giemsa-stained blood smears; 2 μl of blood samples was taken
at 48 and 96 hours).
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To assess the drug concentrations in mice, 25-μl samples of peripheral blood were taken
at different times (usually 0.5, 1, 2, 4, 6, or 8 hours and 23 hours after the first dosing),
mixed with 25 μl of MilliQ H2O, and immediately frozen on a thermal block at −80°C. The
treated mice that reached the limit of detection by standard flow cytometry (<0.01% from
total circulating erythrocytes) were maintained until day 60 of the assay with a chimerism
>50% of total circulating erythrocytes by regular injection of human erythrocytes every
3 or 4 days. During the follow-up period, 2-μl blood samples were taken every 2 or 3
days and analyzed by flow cytometry with a limit of quantification of 0.1%. The first day
of parasitemia detection was recorded. The mice were deemed cured (free of detectable
parasites) if no recrudescence was detected by day 60.
As biological controls, (i) parasite growth in untreated and/or vehicle-treated individuals
was evaluated from days 1 to 5; (ii) the parasite burden was measured from days 1 to 5 of
the assay in individuals treated with a fixed dose of a standard antimalarial; and (iii) the
distribution of parasitemia at day 1 of the assay for all individual mice tested in the assay
was compared to parasitemia distributions in previous experiments.
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For data analysis, ED90 and area under the curve at the ED90 (AUCED90) were defined and
calculated according to Angulo-Barturen et al. (14). ED90 is the effective dose in milligrams
per kilogram that reduced parasitemia by 90% at day 5 compared to vehicle-treated mice.
AUCED90 is the average estimated daily exposure that reduced parasitemia from peripheral
blood at day 5 of the assay by 90% compared to vehicle-treated mice. The ED90 was
calculated by fitting the variable Y = log10 (parasitemia at day 5 of the assay) and the
variable X = log10 (dose level in milligrams per kilogram) defined as an ordered pair for
every individual of the study. The AUCED90 was calculated by fitting the variable Y = log10
(parasitemia at day 5 of the assay) and the variable X = log10 (AUC of compound during
the first 23 hours after the first drug administration, in ng·hour/ml] defined as an ordered
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pair for every individual of the study. The equation used to fit the data is Y = bottom + (top
− bottom)/(1 + 10((logED50 − X) × Hill Slope)). The ED90 and AUCED90 were calculated
by interpolation of the X value that corresponded to antilog10 [Y = “Top” − 1] in each
respective best fitted curve (14).
The time of exposure in days (te) and the average concentration in blood (C; in
nanograms per milliliter) for killing all P. falciparum parasites in mice were interpolated
from a multivariate logistic regression. The fitted function links the dichotomic response
variable termed the therapeutic response (Tr), which takes Tri = 0 if an individual shows
recrudescence and Tri = 1 if no recrudescence was detected at day 60 of the assay, and
the explanatory variables te and C. These parameters offered direct empirical estimates of
the time of exposure and concentration in blood to kill a defined number of circulating
parasites, which was typically 108 per mouse. The regression formula is as follows:
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P (T r = 1 ∣ te, C) =

1
1 + e−(α + β1te + β2C)
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Data were analyzed using GraphPad Prism 7.0 (GraphPad Software), Excel 2016
(Microsoft), and R free software (www.r-project.org). Phoenix WinNonlin v.7.0 (Certara)
was used for PK noncompartmental analysis. Animal experiments performed at TAD were
approved by the TAD Institutional Animal Care and Use Committee. The Committee is
certified by the Biscay County Government (Bizkaiko Foru Aldundia, Basque Country,
Spain) to evaluate animal research projects from Spanish institutions according to point
43.3 from Royal Decree 53/2013 (BOE-A-2013-1337). All experiments were carried out in
accordance with European Directive 2010/63/EU. The results from the animal experiments
are reported following Animal Research: Reporting of In Vivo Experiments (ARRIVE)
guidelines (www.nc3rs.org.uk/arrive-guidelines), except for disclosure of business trade
confidential information.
Prediction of the efficacious dose in humans based on Pf NSG mouse PK/PD
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The prediction of the first efficacious dose in humans was based on the following: (i)
minimum parasiticidal concentration (MPC) as evaluated from a population-based PK/PD
modeling of experimental data from NSG mouse studies. One team at MMV used Monolix
software, and another at Sanofi used a NonMem software to build a PK/PD model. Both
teams reached a similar median estimate value of 20 ng/ml as the MPC; (ii) Kkill of the
compound as deduced from in vitro logPRR (five in 48 hours). However, a conservative
approach was recommended by MMV to use a capped value of 3 based on values
observed for endoperoxides when tested in humans; (iii) predicted human PK parameters as
determined by an allometric approach. For the allometric scaling of clearance from animal
data, we used two methods: Mahmood rules and the Fixed exponent method. These led
to the prediction of a low to a very low MMV688533 clearance in humans, 3.6 and 1.4
liters/hour, respectively, that corresponded to a total clearance of <5% of hepatic blood flow.
This, in turn, corresponded to a predicted half-life of 103 and 277 hours, respectively, in
humans. The volume of distribution (Vdss) relying on allometry method with an exponent
of 1 was predicted to be as large as 540 liters for a 70-kg human; (iv) a biopharmaceutical
model (GastroPlus) used to estimate Fa% versus dose in humans and verified on rat and dog
PK data.
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Evaluation of genotoxicity; PK studies in mice, rats, and dogs; safety pharmacology
profiling; and patch clamp electrophysiological hERG assays
These are described in the Supplementary Materials.
P. falciparum stage-specificity assays
In vitro IC50 values were determined by incubating parasites for 72 hours across a range
of 10 different concentrations of antimalarial compounds plus two no-compound controls.
Stage specificity assays used a modified protocol with tightly synchronized parasites tested
at different starting stages of the asexual blood-stage cycle (15).
P. falciparum resistance selections
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Single-step selections for MMV688533 resistance used triplicate flasks of 2 × 109 Dd2
B2 parasites exposed to 5× to 14× the IC50 (25 to 80 nM) of MMV688533. Selections
were terminated after 60 days because resistant parasites had not emerged. Ramping
selections used triplicate flasks of 2 × 108 3D7-A10 parasites exposed to MMV688533
at concentrations that increased gradually from 1× to 10× the IC50 (5.5 to 60 nM) over a
6-month period. Resistant clones were obtained from bulk cultures of the ramping selections
by limiting dilution, and four clones were selected for WGS. MMV688533 growth inhibition
was determined by staining the parasites with SYBR Green and MitoTracker Deep Red (Life
Technologies) followed by flow cytometry (Accuri C6, BD Biosciences) (43). IC50 values
were derived from growth inhibition data using nonlinear regression (Prism 9.0, GraphPad).
Unless stated otherwise, all drug assays were performed on at least four separate occasions
(as biological repeats) with two technical replicates.
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WGS analysis
The 3D7-A10 parent and MMV688533-resistant clones were subjected to WGS using an
Illumina TruSeq DNA PCR (polymerase chain reaction)–Free library preparation protocol
and a MiSeq sequencing platform, as previously described (44).
Genome editing
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Mutations in PfACG1 and PfEHD that were identified from the in vitro selections were
validated by engineering them into the parental 3D7-A10 line using an “all-in-one” pDC2
based CRISPR-Cas9 plasmid (45) (fig. S2A). The Cas9 in this plasmid is derived from
Streptococcus pyogenes, has been codon-optimized for P. falciparum, and is under the
expression of a calmodulin promoter. The plasmid also contains a human dhfr (hdhfr)
selectable marker (that confers resistance to WR99210) under a P. chabaudi dhfr-ts (PcDT)
promoter and the sequence encoding the guide RNA (gRNA) under a U6 promoter. gRNAs
were selected using the online tool ChopChop based on their proximity to the mutation
of interest, guanine-cytosine (GC) content, and the absence of poly adenine/thymine
(A/T) tracts (http://chopchop.cbu.uib.no). The gRNA primers were annealed with Bbs I
overhangs using PCR and cloned into a Bbs I–linearized pDC2 CRISPR-Cas9 vector. The
donor templates, also supplied on the same plasmid, had >300 bp of homology flanking
the mutation of interest. These fragments were first amplified by PCR and cloned into
pGEM-T vectors to introduce shield mutations by site-directed mutagenesis. Shielded donor
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fragments were then amplified by PCR and cloned into the Eco RI/Aat II–linearized pDC2
CRISPR-Cas9 vector by In-Fusion cloning (Takara). Last, the plasmids were midi-prepped
for transfections.
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Parasites were electroporated with purified circular plasmid DNA as previously described
(46). Briefly, a 2.5-ml culture of 3D7-A10 or sel. 533-CL1 (≥5% rings) was washed and
resuspended in 220 μl of 1× Cytomix. This mixture was then added to 50 μg of plasmid
DNA and electroporated at a voltage of 0.31 kV and a capacitance of 950 μF inside
2-mm-gap cuvettes (Bio-Rad) using a Gene Pulser (Bio-Rad) (47). Starting 1 day after
the transfections, the cultures were selected for 6 days with 2.5 nM WR99210 (46) and
maintained thereafter in complete media until recrudescence. Gene editing was assessed via
Sanger sequencing of blood PCR (Bioline) from bulk cultures. Edited parasite clones were
obtained by limiting dilution. The parasites were then assayed for resistance to MMV688533
using flow cytometry.
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Both the mycobacteriophage Bxb1 serine integrase system (47) and CRISPR-Cas9 gene
editing tools were used to generate the doubly tagged parasite line expressing PfACG1
eGFP and PfEHD-3×HA fusion proteins. Briefly, NF54attB parasites (41) were first
cotransfected with an integrase-expressing plasmid pINT and a donor attP-containing
plasmid pDC2-pfacg1-eGFP. This donor plasmid also contained a blasticidin-S deaminase
(BSD) selectable marker that confers resistance to blasticidin hydrochloride (48). The
integrase plasmid pINT contained a Neomycin selectable marker that confers resistance
to geneticin [G418 (49); fig. S2B]. Transfections were done as described above, and the
cultures were maintained in G418 (250 μg/ml) + BSD media (2 μg/ml) for 6 days after
transfection, followed by BSD media (2 μg/ml) until recrudescence. Sorbitol-synchronized
eGFP-tagged ring-stage clonal parasites obtained by limiting dilution were then transfected
with the codon-optimized all-in-one plasmid containing a 1.1-kb pfehd donor fragment
consisting of two 3′ homology sequences flanking the 3×HA tag (fig. S2C). These
transfections were selected with 2.5 nM WR99210 (50) until recrudescence. Successful
gene tagging was confirmed via PCR, Sanger sequencing, and immunofluorescence assays.
cKD parasite studies
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Generation of cKD parasite lines—To investigate the interaction between
MMV688533, PfACG1, and PfEHD, we used CRISPR-Cas9 to generate parasite cell
lines stably expressing the TetR-DOZI-RNA aptamer module for conditional regulation of
target gene expression. These transgenic lines also contained the reporter construct Renilla
luciferase (RLuc), the selection marker BSD, and a C-terminal 2×HA epitope tag (17).
To construct the donor plasmids, PCR-amplified right homology regions and BioXP3200
System–synthesized DNA fragments corresponding to the left homology regions fused to the
recodonized 3′-end of each target gene, as well as the target-specifying gRNA sequences,
were cloned via Gibson assembly into the pSN054 linear vector (51). The final constructs
were confirmed by restriction digests and Sanger sequencing. Transfections into Cas9- and
T7 RNA polymerase–expressing NF54 parasites were carried out by preloading erythrocytes
with the donor plasmids as described previously (52). Cultures were maintained in 500 nM
aTc (Sigma-Aldrich, 37919) and blasticidin-S (2.5 μg/ml; RPI Corp B12150-0.1). Parasite
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cell lines stably integrating the donor plasmids were monitored via Giemsa smears and RLuc
measurements.
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Western blotting of cKD parasite lines—PfACG1 and PfEHD cKD parasites
were cultured with 50 nM aTc or without aTc to maintain and down-regulate protein
expression, respectively. Proteins were then extracted after 72 hours via saponin lysis
and resuspended in lysis buffer that consists of 4% SDS and 0.5% Triton X-114 in
1× PBS. Proteins were separated on Mini-PROTEAN TGX precast gels (4 to 15%
gradient) in tris-glycine buffer, transferred to a polyvinylidene fluoride membrane using
the Mini Trans-Blot Electrophoretic Transfer Cell System, and blocked with skim milk
(100 mg/ml) in TBS/Tween. Membrane-bound proteins were probed with mouse anti-HA
(1:3000; Sigma-Aldrich H3663) and rabbit anti–glyceraldehyde-3-phosphate dehydrogenase
(1:5000; Abcam AB9485) primary antibodies and anti-mouse (1:5000; Thermo Fisher
Scientific 62-6520) and anti-rabbit (1:5000; Cell Signaling Technology 7074S) horseradish
peroxidase–conjugated secondary antibodies. After incubation in SuperSignal West Pico
Chemiluminescent substrate (Thermo Fisher Scientific PI34080), protein blots were imaged
and analyzed using the ChemiDoc MP System and Image Lab 5.2.0 (Bio-Rad).
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cKD proliferation assays—To assess the effect of conditionally perturbing PfACG1
and PfEHD expression on parasite growth, synchronous ring-stage parasites cultured in
the presence (50 and 3 nM) or absence of aTc were cultured in triplicate in a 96-well
U-bottom plate (Corning, 62406-121). Luminescence signals were taken at 0, 72, and 120
hours after invasion using the Renilla-Glo(R) Luciferase Assay System (Promega E2750)
and the GloMax Discover Multimode Microplate Reader (Promega). The luminescence
values in the knockdown conditions were normalized to aTc-treated (100% growth) and
chloroquine-treated (200 nM) samples (no growth) as controls and results were analyzed
using GraphPad Prism (version 8; GraphPad Software).
Compound susceptibility assays with cKD parasite lines—A stock solution of
MMV688533 was dispensed into 96-well U-bottom plates and serially diluted in complete
medium to yield final concentrations ranging from 0.3 to 160 nM. Synchronous ring-stage
PfACG1 and PfEHD cKD parasite lines, as well as a control cell line expressing an aptamer
regulatable fluorescent protein, were maintained in the presence (500 nM) or absence of
aTc and were distributed into the drug plates. DMSO- and chloroquine-treated samples (200
nM) served as reference controls. Luminescence was measured after 72 hours as described
above, and median effective concentration (EC50) values were obtained from corrected
dose-response curves using GraphPad Prism.
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Immunofluorescence assays
Indirect immunofluorescence studies were performed in suspension. Cells were fixed in 4%
(v/v) formaldehyde (Thermo Fisher Scientific) for 1 hour at room temperature, followed by
a second fixation step supplementing the 4% formaldehyde solution with 1 mM cysteine
and CaCl2 and subsequent incubation overnight at 4°C. Cells were then permeabilized
on ice using 0.05% Triton X-100 in 1× PBS for 5 min. Autofluorescence was quenched
using a 50 mM glycine treatment for 10 min. After two washes in 1× PBS, the cells were
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resuspended in 1% (w/v) bovine serum albumin (BSA) in 1× PBS blocking buffer and were
then incubated with the appropriate dilution for each primary antibody used: 1:200 for rabbit
anti-ERD2 (BEI Recourses), anti-PMT (provided by C. B. Mamoun), anti-PDI [mouse
anti-PDI (1D3), Enzo Life Sciences], rabbit or mouse anti-GFP [Takara (Clontech), Roche],
and rabbit anti-HA antibodies (Sigma-Aldrich); 1:50 for rabbit anti-Rab5A, -Rab5C, or
-Rab11A and rat anti-Rab5B or Rab7 (provided by G. Langsley); 1:200 for anti-coronin
(provided by J. Baum); 1:200 for anti-ACP (provided by G. McFadden); 1:200 for anti-K13
(22); and 1:200 for anti-PfCRT antibodies (53), followed by incubation with corresponding
species-specific secondary antibodies (Alexa Fluor 488-, 594-, or 647-conjugated goat anti
mouse or -rabbit antibodies; Thermo Fisher Scientific) diluted 1:2000 in 1% BSA in 1×
PBS. MitoTracker Red CMXRos (Thermo Fisher Scientific) was used to stain mitochondria.
HCS LipidTOX Deep Red Neutral Lipid Stain and Nile Red (Invitrogen) were used to
stain neutral lipid bodies according to the protocol provided by the manufacturer. Thin
blood smears of stained RBCs were prepared on microscope slides and mounted with
coverslips using Prolong Diamond Antifade Mountant with 4′,6-diamidino-2-phenylindole
(DAPI; Thermo Fisher Scientific). Parasites were imaged using a Nikon Eclipse Ti-E wide
field microscope equipped with an sCMOS camera (Andor) and a Plan-apochromate oil
immersion objective with 100× magnification (1.4 numerical aperture). A minimum of 27
Z-stacks (0.2-μm step size) were photographed for each parasitized RBC. NIS-Elements
imaging software (Version 5.02, Nikon) was used to control the microscope and camera,
deconvolve the images (using 25 iterations of the Richardson-Lucy algorithm for each
image), and perform 3D reconstructions (22). ImageJ (Fiji) (version 2.0.0-rc-68/1.52h) was
used to crop the images, adjust brightness and intensity, overlay channels, and prepare
montages.
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Statistical analysis
Mann-Whitney U tests were performed (using Prism 9.0; GraphPad) to test for statistical
significance between isogenic parasite lines in their drug IC50 values (Fig. 2B and table S3).
Wilcoxon rank sum tests were used to identify significant differences in drug susceptibility
between P. falciparum field isolates (Table 1).
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Fig. 1. The preclinical antimalarial candidate MMV688533 has a fast rate of antiplasmodial
activity that offers potent single-dose activity against P. falciparum infection in a humanized
mouse model.
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(A) Structural representation showing the optimization of the acylguanidine series from
the initial hit MMV668603 and the lead MMV669851 to the candidate MMV688533. (B)
Means ± SD values of viable P. falciparum parasites were determined daily for 5 days after
in vitro incubation with MMV688533 at 10× the IC50. Dihydroartemisinin, chloroquine,
pyrimethamine, and atovaquone were included as reference antimalarial drugs. (C) Means
± SD values of P. falciparum viability determined daily for 5 days after MMV688533
treatment at doses corresponding to 1×, 3×, 10×, or 30× the IC50. (D) Compound efficacy
was assessed by measuring the initial clearance and time of recrudescence of P. falciparum
in the peripheral blood of humanized mice that had been administered single doses of
MMV688533 ranging from 0.5 to 75 mg/kg (two mice per dose). DHA (50 mg/kg) and
vehicle were included as controls. (E) Concentration of MMV688533 in serial blood
samples obtained after administering different doses to P. falciparum–infected humanized
mice assayed in (D). LOQ, limit of quantification.
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Fig. 2. MMV688533 antiplasmodial activity is unrelated to existing antimalarials and selects for
low-grade resistance mediated in part by mutations in PfACG1 and PfEHD.
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(A) In vitro asexual blood-stage susceptibility assay showing MMV688533 activity in
early and late rings, early and late trophozoites, and schizonts. IC50 values are shown as
means ± SEM (N > 3, n = 2). (B) MMV688533 mean ± SEM IC50 values of selected
(sel.) (533-CL1, 533-CL2, and 533-CL4), edited (ed.) (PfACG1G98V, PfACG1W286R, and
PfEHDD218Y) lines, and the sel. ed. line 533-CL1EHD-D218Y compared to the 3D7-A10
parental line. N > 6, n = 2; **P < 0.01 and ***P < 0.0005; ns, not significant. (C)
Western blot data showing effective reduction in PfACG1 and PfEHD protein levels upon
removal of aTc, as detected using antibodies specific to the 2×HA tag added to the C
terminus of each protein. Parasite survival was measured by quantifying expression of
the integrated RLuc cassette (fig. S1), in the presence (50 nM) or absence of aTc. Data
represent the mean of three biological replicates and are normalized to a fully inhibitory
concentration of chloroquine (200 nM). (D) Dose-response curves for MMV688533 against
PfACG1 and PfEHD ckD asexual blood-stage (ABS) parasites expressing wild-type or
substantially reduced levels of each protein upon culturing with 500 nM aTc or no aTc,
respectively. (E) G98V and W286R mutations in PfACG1 and a combination of both
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G98V in PfACG1 and D218Y in PfEHD in sel. ed. 533-CL1EHD-D218Y did not confer cross
resistance to a panel of known antimalarial drugs compared to the 3D7-A10 parent. Means
± SEM; N > 3, n = 2. (F) Fluorescence microscopy images of fixed NF543×HA-EHDattB
ACG1-eGFP parasites stained with either anti-GFP (green) antibodies or anti-HA (magenta)
antibodies. Nuclei were stained with DAPI (blue). Scale bars, 2 μm. (G) Fluorescence
microscopy image of fixed and doubly stained NF543×HA-EHDattB-ACG1-eGFP parasites
using anti-GFP (green) and anti-HA (magenta) antibodies. Nuclei were stained with DAPI
(blue). Scale bar, 2 μm. (H to L) Fluorescence microscopy images and 3D reconstructions
of fixed NF543×HA-EHDattB-ACG1-eGFP parasites costained with antibodies to anti-GFP
(green) and (H) anti-PfCRT antibodies, (I) LipidTOX neutral lipid stain, (J) anti-PDI, (K)
anti-ERD2, or (L) anti-Rab5A (red) antibodies. Nuclei were stained with DAPI (blue). Scale
bars, 2 μm. (M to Q) Fluorescence microscopy images and 3D reconstructions of fixed
NF543×HA-EHDattB-ACG1-eGFP parasites costained with antibodies to anti-HA (magenta)
and (M) anti-PfCRT antibodies, (N) LipidTOX neutral lipid stain, (O) anti-PDI, (P) anti
ERD2, or (Q) anti-coronin (cyan) antibodies. Nuclei were stained with DAPI (blue). Scale
bars, 2 μm.
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11 (11)
4.4 (11)
4.8 (11)

Chloroquine

Piperaquine

Mefloquine

DHA/artesunate

Sci Transl Med. Author manuscript; available in PMC 2022 July 21.
1.7 (9)

6.6 (10)

7.9 (10)

347 (10)

0.6 (2)

37.2 (2)

25.8 (2)

10.9 (2)

9.7 (2)

FC27
(Mean, N)

P. falciparum

Laboratory
lines

1.1 (2)

8 (2)

111.2 (2)

100.3 (2)

19 (2)

K1
(Mean, N)

P. falciparum

Laboratory
lines

11.2
(6; 8.1–20.7)
0.6*
(6; 0.3–2.4)

64.8***
(15; 38.3–283)
60.8***
(15; 17.6–130)
10.0
(15; 4.9–41.9)
1.2***
(15; 0.4–4.3)

17***
(143; 2.1–346)
5.1***
(140; 0.3–26)
8.3***
(120; 0.5–24)
1.5
(142; 0.1–9.0)

46.6*
(6; 15.0–135)

36.4*
(6; 11.6–114)

12.0
(6; 5.4–19.9)

18.9
(15; 5.3–39.2)

1.3
(143; 0.02–6.3)

Median
(N; range)

P. vivax

Clinical field
isolates (Papua,
Indonesia)

Median
(N; range)

P. falciparum

Clinical field
isolates (Papua,
Indonesia)

Median
(N; range)

P. falciparum

Clinical field
isolates
(Uganda)

DHA was tested on 3D7, Dd2, and Ugandan parasites, whereas artesunate was tested on FC27, K1 and Papua/Indonesian parasites.

†

P < 0.001.

***

P < 0.05.

*

1.9 (4)

MMV688533

1.9 (9)

Dd2
(Median, N)

3D7
(Median, N)

Antimalarial

†

P. falciparum

P. falciparum

3.0 (4)

Laboratory
lines

Laboratory
lines

3D7 and FC27 are chloroquine sensitive, whereas Dd2 and K1 are chloroquine resistant. The potency of the other antimalarials was compared to
MMV688533 using a Wilcoxon rank sum test.

In vitro activity against Plasmodium culture-adapted lines or field isolates was calculated from dose-response curves and is shown as median or mean
half-maximal growth inhibition (IC50) in nanomolar concentrations. For the laboratory lines, numbers of independent repeats are shown in parentheses.
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MMV688533 activity (in nanomolar) against Plasmodium parasite lines and field isolates.
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PF3D7_0304200
PF3D7_0510100
PF3D7_0511500
PF3D7_1464700

EHD-containing protein (PfEHD)

Conserved Plasmodium protein

RNA pseudouridylate synthase, putative

ATP synthase (C/AC39) subunit, putative

Stop mutation resulting from a deletion-induced frameshift.

*

PF3D7_0910300

Gene ID

Conserved Plasmodium protein (PfACG1)

Gene product

L260I

wt

wt

wt

wt

wt

wt

wt

W286R

1.7 × IC50

3.1 × IC50
W286R

ed. 3D7
ACG1W286R

sel.
533-CL2

wt

K2762E

wt

wt

wt

wt

D218Y

G98V

T92*
wt

4.6 × IC50

sel.
533-CL4

wt

wt

wt

wt

G98V

1.8 × IC50

ed. 3D7
ACG1G98V

wt

wt

wt

D218Y

wt

1.2 × IC50

ed. 3D7
EHDD218Y

Amino acid substitution

2.5 × IC50

sel.
533-CL3

wt

wt

N1042H

wt

G98V

2.2 × IC50

sel. 533CL1

wt

wt

N1042H

D218Y

G98V

6.2 × IC50

sel. ed.
533-CL1EHD-D218Y

ed. 533-CL1EHD-D218Y clone was generated by CRISPR-Cas9 editing the EHD D218Y mutation into the selected 533-CL1 clone. wt, wild-type; ATP,
adenosine 5′-triphosphate.

ACG1G98V, and EHDD218Y strains were gene-edited (ed.) using CRISPR-Cas9 to introduce the designated mutation into 3D7-A10 parasites. The sel.

for whole-genome sequencing. Fold IC50 increases compared to the parent 3D7-A10 are indicated below the clone names. P. falciparum ACG1W286R,

Four parasite clones (sel. 533-CL1 from flask 1, sel. 533-CL2 and 533-CL3 from flask 2, and sel. 533-CL4 from flask 3) were generated from selections
(sel.) and named after the last three digits of the selecting compound (MMV688533) followed by the clone number. These clones were then chosen

Mutations identified in MMV688533-selected resistant P. falciparum clones and validated using CRISPR-Cas9 gene editing.

Murithi et al.
Page 29

Sci Transl Med. Author manuscript; available in PMC 2022 July 21.

